From Defensible to Predictive: How High-Functioning MLR Teams Are Evolving Their Risk Assessment Approach

For several years, FDA's Office of Prescription Drug Promotion (OPDP) maintained a relatively low enforcement profile. For example, between 2022 and 2024, the Agency issued only 14 Untitled and...